The UK’s medical technology sector is one of the most dynamic parts of the life sciences economy. According to the International Trade Administration, it supports more than 138,000 jobs, contributes 31% of life sciences turnover and includes more than 4,000 UK businesses, with the number of active medtech companies growing by more than 200% over the past decade.

Within this national picture, Nottingham has established itself as an important centre for healthcare, life sciences and medical technology. The city brings together clinical expertise, academic research, entrepreneurial talent and specialist facilities, creating the conditions companies require to move from early-stage ideas to patient-focused products and services.

At the core of this ecosystem is MediCity Nottingham, a specialist community where life science and healthcare innovators can access the space, business support and industry connections they need to translate research, technology and clinical insight into real-world impact.

Why MediCity Nottingham Matters

Based within the iconic Art Deco Boots headquarters in Nottingham, MediCity Nottingham provides a launchpad for companies working across medtech innovation.

Its mix of first-rate laboratories, offices, shared facilities and community support helps reduce some of the practical barriers that early-stage companies face when developing complex healthcare products. Just as importantly, its location places tenants close to Queen’s Medical Centre and the University of Nottingham’s Medical School, creating valuable opportunities for collaboration with clinicians, researchers and industry experts. This academic and testing corridor is powerfully complemented by the adjacent Medical Technologies Innovation Facility (MTIF) operated by Nottingham Trent University, giving companies direct access to world-class cleanrooms, advanced prototyping, and cutting-edge laboratory infrastructure.

For companies seeking commercial validation, the link with Boots UK’s headquarters also provides visibility with healthcare and retail health decision-makers. Combined with Enterprise Zone status, strategic alignment with the East Midlands Combined County Authority’s (EMCCA) high-priority regional life sciences strategy and access to the wider Pioneer Group network, MediCity offers both the physical infrastructure and connected ecosystem needed to support medtech and life science businesses as they grow.

Innovation in Action

The companies based within MediCity’s community reflect the breadth of healthcare innovation taking place in Nottingham today. Their work spans medical devices, diagnostics and screening, biomaterials, therapeutics, drug discovery, regenerative medicine, and life science – illustrating how specialist space and support can help scientific ideas progress towards clinical, regulatory and commercial milestones.

Improving Neonatal Monitoring

SurePulse Medical has been based at MediCity since 2018. From this base, the University of Nottingham spinout – is developing wireless heart rate monitoring technology designed to support clinicians caring for newborn babies. A recent study published in The Journal of Maternal-Fetal & Neonatal Medicine confirmed that the SurePulse VS wireless heart rate monitor is feasible and acceptable for use in preterm infants in UK neonatal units.

Wireless monitoring can help reduce the need for intrusive wired equipment whilst supporting early parent-infant bonding – an important consideration in neonatal care, where technology must work alongside compassion, reassurance and family-centred practice.

Backing Regenerative Approaches to Eye Care

NuVision Biotherapies is a University of Nottingham spin-out focused on helping accelerate the healing of eye conditions. The company’s therapies harness amniotic membrane, the tissue that surrounds babies in the womb, to support wound healing after eye surgery and manage conditions including ulcers, burns, glaucoma and infections.

This year, the company raised £4.8m in a funding round led by the Midlands Engine Investment Fund II through Mercia Ventures, with participation from the University of Nottingham and Pioneer. The funding will help NuVision to meet growing demand for its products by scaling up the business and entering more international markets.

Pioneer’s support for NuVision has included seed funding, participation in its Accelerator Programme and further investment to help advance its first two products. It is a strong example of how long-term ecosystem support can help life science companies move from academic roots towards international commercial opportunity.

Advancing Blood-Based Cancer Screening

Diagnostics innovation is another important part of MediCity’s story. Freenome is focused on blood-based early cancer detection, with landmark milestones achieved in summer 2026. These include the FDA granting Breakthrough Device Designation for its blood-based SimpleScreen™ lung cancer screening test in August 2026, alongside an official late-July FDA approval for SimpleScreen™ CRC—a new blood-based colorectal cancer screening programme.

Building on this momentum, Freenome officially debuted as a publicly traded company on the Nasdaq stock exchange in July 2026, reflecting the growing commercial momentum behind diagnostics that could help identify disease earlier and support more proactive healthcare.

Building Evidence for Next-Generation Bone Regeneration

Another key member of the community is Locate Bio, which is developing advanced regenerative medicine technologies, including approaches designed to support bone regeneration. Its recent peer-reviewed study on rhBMP-2 delivery highlights the strong scientific evidence base behind its LDGraft™ product and the importance of precisely controlled delivery systems for bone regeneration.

For patients and clinicians, this kind of innovation has the potential to improve patient outcomes in complex procedures where effective bone healing is critical. For the wider ecosystem, it shows the importance of pairing deep scientific capability with the facilities, partners and evidence generation needed to progress regulated healthcare products.

Translating Biomaterials into Commercial Medical Devices

4D Biomaterials (4D Medicine) is a spin-out from the University of Birmingham and the University of Warwick. It is working to commercialise a new class of materials – liquid resins that can be printed into solid 3D scaffold implants to help patients recover from major medical procedures. The composition of the resins is protected by a family of patents exclusively licensed to the company as part of the spin-out process.

With a number of de-risking milestones behind it, 4D Medicine is now progressing the final close of its rolling Series A raise. The funds will be used to apply for regulatory clearance of its first medical device and to accelerate commercialisation.

4D Medicine’s trajectory demonstrates how MediCity can support the commercialisation journey from early scientific concept through to investment readiness, regulatory approvals and market entry.

Accelerating Translational Drug Discovery

Translational contract research organisation Inaphaea BioLabs moved into MediCity in 2023 and is going from strength to strength. A spinout from ValiRx Plc, the company aims to improve the translation of early drug discovery projects towards the clinic by providing cell-based assays specialising in oncology and women’s health.

Inaphaea recently completed an evaluation of a second-generation RNA helicase inhibitor from The Royal Institute for the Advancement of Learning, McGill University and The Institute for Research in Immunology and Cancer – Commercialization of Research. The outcomes of the evaluation prompted ValiRx to negotiate an exclusive licence for the asset and to fund further preclinical development, highlighting the critical value of Inaphaea’s in-house capabilities at its MediCity laboratories.

What our Community Has to Say

Tenant perspectives show how MediCity’s flexible space, community model and wider Pioneer network can help companies adapt as they grow.

Dr James Carpenter, CEO of SurePulse Medical, said: “MediCity has been really flexible in allowing us to add and take away rooms as the needs of our business have evolved. We’re shoulder to shoulder with like-minded companies and we’ve been on the Pioneer Investment Readiness Programme which enabled us to refine our investment pitch and successfully raise funds.”

Dr Andrew Naylor, Chief Operating Officer at 4D Medicine, commented: “Being based at MediCity has been hugely beneficial throughout our six-year journey from a start-up to the business we are today. Access to high-quality laboratory and office space, with the flexibility to expand as we have grown, has given us the right facilities at each stage of our development. The addition of cleanroom space will also provide important capabilities for our next phase of growth. Beyond the facilities themselves, MediCity brings together companies at similar stages of development, creating a supportive community of like-minded people that is great to be part of.”

Simon Alexander, Manager of Lab Operations at Freenome, said: “Being based at MediCity has played an important role in Freenome’s development over the past 7 years. It has provided us with a supportive, well-connected environment in which to grow, while giving us access to valuable expertise, collaboration opportunities and the facilities needed to innovate. The strong community at MediCity has helped us build lasting relationships, respond to new opportunities and continue developing our business with confidence. We are proud of our long association with MediCity and believe it has been an important part of our success and continued growth.”

Dr Mark Eccleston, Director of Inaphaea BioLabs, said: “Being based at MediCity has helped us feel part of a wider community while growing Inaphaea. People are approachable and genuinely willing to help each other, and practical benefits such as the OBN purchasing discounts make a real difference to smaller companies that could not access those savings alone.”

Nottingham as a Launchpad for Healthcare Innovation

The MediCity Nottingham community shows how specialist infrastructure, clinical and academic links and investor support can combine to help healthcare innovation progress from early-stage research to commercial opportunity.

For ambitious medtech, life science and healthcare companies looking for adaptable space, practical support and a connected innovation community, MediCity Nottingham offers an established launchpad in the heart of one of the UK’s leading healthcare and life science ecosystems.